The study was limited by the high heterogeneity in the insulin dose arm, and we did not include the long-acting GLP-1 agonists (semaglutide and dulaglutide) because few studies assessed their role in T1DM. This evidence concerns the gene GCG and type 1 diabetes mellitus.